Orchid
San Francisco
About Orchid
Orchid is a reproductive technology startup that is capable of detecting rare genetic disorders. Orchid’s preconception system analyzes both partners’ genomes and assesses genetic predispositions to common diseases, including heart disease, stroke, schizophrenia, Alzheimer’s disease, breast cancer, and diabetes. Orchid results are developed with world-class experts in reproductive medicine and genetics to give its clients the most accurate results. Orchid offers a “Couple Report” that utilizes an at-home saliva test to analyze each person’s genomes to detect the probability of genetic risks, then models how their DNA together will combine in a future child. If elevated risk is detected, Orchid provides insights to help couples monitor biomarkers, adapt their diet or elect for procedures, such as in vitro fertilization. It was founded by Noor Siddiqui in 2019 and is headquartered in San Francisco, California.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $16.5M
- Funding stage: Seed
- Last round: Seed (Dec 2023)
- Website: orchidhealth.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical, mHealth
Social Profiles
Canonical: https://fsome.com/organization/orchid-118878 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.